[MINIREVIEW]The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance

Sandrine M. Soh; Yeongjun Kim; Chanwoo Kim; Ui Soon Jang; Hye-Ra Lee

doi:10.1007/s12275-021-1348-5

Articles

Page Path: HOME > J. Microbiol > Volume 59(9); 2021 > Article

Review
[MINIREVIEW]The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance: Sandrine M. Soh ¹, Yeongjun Kim ¹, Chanwoo Kim ¹, Ui Soon Jang ¹, Hye-Ra Lee ^1,2; Journal of Microbiology 2021;59(9):807-818.
DOI: https://doi.org/10.1007/s12275-021-1348-5
Published online: August 27, 2021

¹Department of Biotechnology and Bioinformatics, College of Science and Technology, Korea University, Sejong 30019, Republic of Korea, ²Department of Lab Medicine, College of Medicine, Korea University, Seoul 02841, Republic of Korea¹Department of Biotechnology and Bioinformatics, College of Science and Technology, Korea University, Sejong 30019, Republic of Korea, ²Department of Lab Medicine, College of Medicine, Korea University, Seoul 02841, Republic of Korea

Corresponding author: Hye-Ra Lee , Tel: +82-44-860-1831,

Received: 30 June 2021 • Revised: 9 August 2021 • Accepted: 9 August 2021

62 Views
0 Download
16 Web of Science
16 Crossref
16 Scopus

Full Article

Abstract

The causative factor of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously mutating. Interestingly, identified mutations mainly occur in the spike (S) protein which interacts with the ACE2 receptor and is cleaved via serine protease TMPRSS2. Some mutated strains are becoming dominant in various parts of the globe because of increased transmissibility as well as cell entry efficacy. Remarkably, the neutralizing activity of monoclonal antibodies, convalescent sera, and vaccines against the variants has been reported to be significantly reduced. Therefore, the efficacy of various monoclonal antibodies therapy and vaccines against these variants is becoming a great global concern. We herein summarize the current status of SARS-CoV- 2 with gears shifted towards the recent and most common genetic variants in relation to transmission, neutralizing activity, and vaccine efficacy.

Keywords: 16S rRNA;diagnostic performance;oral microbiota;random forest;viral encephalitis;viral meningitis

Figure & Data

References

Citations

Citations to this article as recorded by

Understanding the Molecular Actions of Spike Glycoprotein in SARS-CoV-2 and Issues of a Novel Therapeutic Strategy for the COVID-19 Vaccine
Yasunari Matsuzaka, Ryu Yashiro
BioMedInformatics.2024; 4(2): 1531. CrossRef
Complex vaccination strategies prevent the emergence of vaccine resistance
Simon A Rella, Yuliya A Kulikova, Aygul R Minnegalieva, Fyodor A Kondrashov, Ben Ashby, Tim Connallon
Evolution.2024; 78(10): 1722. CrossRef
Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant
Tae-Hun Kim, Sojung Bae, Sunggeun Goo, Jinjong Myoung
Journal of Microbiology and Biotechnology.2023; 33(12): 1587. CrossRef
Analysis of 3.5 million SARS-CoV-2 sequences reveals unique mutational trends with consistent nucleotide and codon frequencies
Sarah E. Fumagalli, Nigam H. Padhiar, Douglas Meyer, Upendra Katneni, Haim Bar, Michael DiCuccio, Anton A. Komar, Chava Kimchi-Sarfaty
Virology Journal.2023;[Epub] CrossRef
Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines
Charlotte Dubé, Sarah Paris-Robidas, Guadalupe Andreani, Cindy Gutzeit, Marc-André D'Aoust, Brian J. Ward, Sonia Trépanier
Vaccine.2022; 40(30): 4017. CrossRef
A tentative tracking of the SARS-Cov2 pandemic in France, based on a corrected SIR model including vaccination effects
Mathilde Varret, François Xavier Martin, François Varret, J.-C.S. Lévy
EPJ Web of Conferences.2022; 263: 01002. CrossRef
Changing Dynamics of SARS-CoV-2: A Global Challenge
Ananya Chugh, Nimisha Khurana, Kangna Verma, Ishita Sehgal, Rajan Rolta, Pranjal Vats, Rajendra Phartyal, Deeksha Salaria, Neha Kaushik, Eun Ha Choi, Mansi Verma, Nagendra Kumar Kaushik
Applied Sciences.2022; 12(11): 5546. CrossRef
The SARS-CoV-2 differential genomic adaptation in response to varying UVindex reveals potential genomic resources for better COVID-19 diagnosis and prevention
Naveed Iqbal, Muhammad Rafiq, Masooma, Sanaullah Tareen, Maqsood Ahmad, Faheem Nawaz, Sumair Khan, Rida Riaz, Ting Yang, Ambrin Fatima, Muhsin Jamal, Shahid Mansoor, Xin Liu, Nazeer Ahmed
Frontiers in Microbiology.2022;[Epub] CrossRef
SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells
Rayhane Nchioua, Annika Schundner, Dorota Kmiec, Caterina Prelli Bozzo, Fabian Zech, Lennart Koepke, Alexander Graf, Stefan Krebs, Helmut Blum, Manfred Frick, Konstantin M. J. Sparrer, Frank Kirchhoff, Tom Gallagher
Journal of Virology.2022;[Epub] CrossRef
Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants
Severino Jefferson Ribeiro da Silva, Suelen Cristina de Lima, Ronaldo Celerino da Silva, Alain Kohl, Lindomar Pena
Frontiers in Medicine.2022;[Epub] CrossRef
Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants
Lili Li, Meiling Gao, Peng Jiao, Shulong Zu, Yong-qiang Deng, Dingyi Wan, Yang Cao, Jing Duan, Saba R Aliyari, Jie Li, Yueyue Shi, Zihe Rao, Cheng-feng Qin, Yu Guo, Genhong Cheng, Heng Yang
Cell & Bioscience.2022;[Epub] CrossRef
Perspectives and Factors Affecting the Preventive Behavior Pertinent to COVID-19 among School Employees in Chiang Mai, Thailand: A Cross-Sectional Study
Pheerasak Assavanopakun, Tharntip Promkutkao, Suchat Promkutkeo, Wachiranun Sirikul
International Journal of Environmental Research and Public Health.2022; 19(9): 5662. CrossRef
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
Karin Hardt, An Vandebosch, Jerald Sadoff, Mathieu Le Gars, Carla Truyers, David Lowson, Ilse Van Dromme, Johan Vingerhoets, Tobias Kamphuis, Gert Scheper, Javier Ruiz-Guiñazú, Saul N Faust, Christoph D Spinner, Hanneke Schuitemaker, Johan Van Hoof, Macay
The Lancet Infectious Diseases.2022; 22(12): 1703. CrossRef
Fundamentals of genomic epidemiology, lessons learned from the coronavirus disease 2019 (COVID-19) pandemic, and new directions
Denis Jacob Machado, Richard Allen White, Janice Kofsky, Daniel A. Janies
Antimicrobial Stewardship & Healthcare Epidemiology.2021;[Epub] CrossRef
Daily Physical Activity and Sleep Measured by Wearable Activity Trackers during the Coronavirus Disease 2019 Pandemic: A Lesson for Preventing Physical Inactivity during Future Pandemics
Hidetaka Hamasaki
Applied Sciences.2021; 11(21): 9956. CrossRef
The adaptation of SARS-CoV-2 to humans
Eduardo Tosta
Memórias do Instituto Oswaldo Cruz.2021;[Epub] CrossRef

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

[MINIREVIEW]The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance

J. Microbiol. 2021;59(9):807-818. Published online August 27, 2021

DOI: https://doi.org/10.1007/s12275-021-1348-5

Related articles